The Food and Drug Administration posted its review Tuesday of the experimental medication ahead of a public meeting later this week.
By Matthew Perrone, Associated Press
Under one scenario, the FDA estimates reducing nicotine could help the U.S. smoking rate could fall as low as 1.4 percent by 2060, down from the 15 percent of adults who smoke now.
By Erin Mershon, Ike Swetlitz, STAT
A government shutdown of the FDA, CDC and NIH will likely have widespread and long-lasting consequences for public health.
By Max Blau, STAT
A wearable device claiming to block the pain of opioid withdrawal has been cleared by the Food and Drug Administration under a new expedited review process.
By Rebecca Robbins, STAT
New findings highlight just how hard it has been for the FDA to keep potentially unsafe supplement ingredients off the market.
By Synclaire Cruel
The Senate passed a measure Thursday allowing people to purchase hearing aids without a doctor's prescription.
By Andrew Taylor, Associated Press
Legislation approved Wednesday by the Republican-controlled Appropriations Committee would prevent the FDA from requiring retroactive safety reviews of e-cigarettes already on the market. But most panel Democrats said the products are dangerous and are targeted at children.
By PBS NewsHour
A promising lung cancer treatment from Cuba is getting attention from U.S. patients, some of whom are already traveling there to try the drug in hopes of stopping their cancer from growing. American doctors can't prescribe CIMAvax because the Food…
In Congress, lawmakers are close to passing a major bill that would increase funding for the FDA, the NIH and the effort to fight opioid abuse. The measure would also introduce more flexible standards for drug approvals, reducing the need…
By Sheila Kaplan, STAT
More than 1,300 lobbyists roamed the halls of Congress on the 21st Century Cures Act, and disclosure reports show most of them were working for pharmaceutical companies.
Support Provided By: Learn more
Educate your inbox
Subscribe to Here’s the Deal, our politics newsletter for analysis you won’t find anywhere else.